Item 8.01 Other Events.
On November 29, 2012, Cytokinetics, Inc. issued a press release announcing the
opening to enrollment of the third and final cohort in ATOMIC-AHF (Acute
Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart
Failure), the ongoing, international, randomized, double-blind,
placebo-controlled Phase IIb clinical trial of an intravenous formulation of
omecamtiv mecarbil. Following a review of the data from the first and second
cohorts in this ongoing Phase IIb clinical trial, the independent data
monitoring committee concluded that the current data supports progression of
this trial.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on
Form 8-K, and is incorporated herein by reference.
Top of the Form
Add
CYTK to Portfolio
Set Alert
Email to a
Friend